ALBERT DAVID LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,164 INR | +1.02% |
|
-2.68% | +19.25% |
| Mar. 31 | Albert David Limited Announces Board Retirement | CI |
| Mar. 14 | Albert David Limited Announces Management Changes | CI |
| Sales 2022 | 3.14B 37.59M | Sales 2023 | 3.42B 40.95M | Capitalization | 2.92B 35.03M |
|---|---|---|---|---|---|
| Net income 2022 | 353M 4.23M | Net income 2023 | 362M 4.34M | EV / Sales 2022 | 0.43 x |
| Net cash position 2022 | 1.69B 20.28M | Net cash position 2023 | 1.98B 23.73M | EV / Sales 2023 | 0.28 x |
| P/E ratio 2022 |
8.61
x | P/E ratio 2023 |
8.08
x | Employees | 1,271 |
| Yield 2022 |
1.69% | Yield 2023 |
1.76% | Free-Float | 35.79% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.02% | ||
| 1 week | -2.68% | ||
| Current month | +8.21% | ||
| 1 month | +2.92% | ||
| 3 months | -18.11% | ||
| 6 months | +40.03% | ||
| Current year | +19.25% |
1 week
1 131.60
1 222.00
1 month
1 096.101 230.00
Current year
962.001 605.00
1 year
555.001 605.00
3 years
430.651 605.00
5 years
255.001 605.00
10 years
115.501 605.00
| Managers | Title | Age | Since |
|---|---|---|---|
Umesh Kunte
CEO | Chief Executive Officer | 55 | 23-02-05 |
| Director of Finance/CFO | - | 20-11-30 | |
| Chairman | 70 | 88-06-19 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 70 | 88-06-19 | |
| Director/Board Member | 66 | 14-03-30 | |
| Director/Board Member | - | 22-05-10 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-03 | 1,164 | +1.02% | 1 130 |
| 24-05-02 | 1,152 | -3.74% | 1,642 |
| 24-04-30 | 1,197 | +0.08% | 492 |
| 24-04-29 | 1,196 | +0.39% | 516 |
| 24-04-26 | 1,191 | +1.62% | 1,267 |
Delayed Quote Bombay S.E., May 03, 2024 at 06:00 am EDT
More quotes
Albert David Limited is engaged in manufacturing and trading of pharmaceutical formulations, infusion solutions, herbal dosage forms and bulk drugs by way of domestic sale or export. The Company offers its products under various categories, which includes parenteral, oral/enteral, topical agents and vision care. Its parenteral consists of amino acids infusion, antimicrobial, anti-leishmaniasis (kalazar), hemostat, neurotropic vitamin, and placenta extract. Its oral/enteral consists of amino acids oral, anthelmintic, anti-microbial, anti ulcerants, anti-vertigo, appetite stimulants, anti-tubercular, hematinic, oral vitamin b complex and expectorant / cough syrup. Its topical agents consist of non-steroidal anti-inflammatory drugs (NSAID). Its vision care consists of anti-glaucoma, anti-infective, tear substitutes and anti-infective with NSAID. It has presence in Southeast Asia, Africa, countries of Middle - East, Europe, United States of America, and Latin America.
Sector
Pharmaceuticals
Calendar
2024-05-28
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +19.25% | 78.8M | |
| +19.98% | 43.67B | |
| +20.67% | 22.51B | |
| +14.75% | 14.6B | |
| +14.32% | 13.74B | |
| +44.72% | 11.91B | |
| -8.37% | 7.04B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +10.21% | 5.42B |
- Stock Market
- Equities
- ALBERTDAVD Stock
